Synaptogenix, Inc. (NASDAQ:SNPX – Get Rating) saw a significant growth in short interest in July. As of July 31st, there was short interest totalling 238,300 shares, a growth of 24.8% from the July 15th total of 190,900 shares. Based on an average daily trading volume, of 61,200 shares, the short-interest ratio is presently 3.9 days. Approximately 5.1% of the shares of the stock are sold short.
Institutional Trading of Synaptogenix
Large investors have recently bought and sold shares of the business. Orion Capital Management LLC acquired a new stake in Synaptogenix during the 4th quarter worth about $34,000. Renaissance Technologies LLC acquired a new stake in Synaptogenix during the 2nd quarter worth about $83,000. Finally, Vanguard Group Inc. grew its holdings in Synaptogenix by 248.9% during the 1st quarter. Vanguard Group Inc. now owns 216,836 shares of the company's stock worth $1,678,000 after acquiring an additional 154,688 shares during the period. 11.23% of the stock is currently owned by institutional investors and hedge funds.
Get Synaptogenix alerts:Synaptogenix Stock Up 5.1 %
Shares of NASDAQ:SNPX traded up $0.36 during trading on Friday, hitting $7.42. 145,902 shares of the company were exchanged, compared to its average volume of 99,143. Synaptogenix has a 1-year low of $3.79 and a 1-year high of $14.50. The business's 50 day moving average is $5.70 and its 200-day moving average is $6.31.
Synaptogenix (NASDAQ:SNPX – Get Rating) last posted its quarterly earnings data on Friday, May 13th. The company reported ($0.47) earnings per share for the quarter.About Synaptogenix
(Get Rating)
Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.
Featured Stories
- Get a free copy of the StockNews.com research report on Synaptogenix (SNPX)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.